Preparation and induction of immune responses by a DNA AIDS vaccine

J. M. Smith, N. J. Leung, Jose V Torres

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In an effort to evaluate the feasibility of developing a safe DNA vaccine for acquired immunodeficiency syndrome (AIDS), we have prepared a plasmid-based immunogen modeled after a naturally occurring noninfectious mutant of the simian immunodeficiency virus (SIV). The mutant SIV genome produces defective virus particles that are noninfectious in vitro and nonpathogenic in vivo in rhesus macaques. Analysis of the mutant genome revealed a 1.6 kb deletion that is in frame and spans integrase, vif, vpx, and most of vpr and results in a pol/vpr gene fusion. This deletion was introduced into the parental pathogenic molecular clone and the U3 region of the 5' LTR was replaced with a cytomegalovirus promoter to produce a candidate DNA vaccine, pIV. After transfection with this plasmid, SIV gag and envelope proteins are expressed and properly processed in vitro. When injected into rabbits, pIV elicited an antibody response to SIV gp130 envelope glycoprotein with titers reaching 1:2048, and a strong lymphoproliferative response to SIV gp130 and whole SIV. The potential to produce defective virus particles in vivo without integrating into the host genome should result in both a strong humoral and cellular immune response in rhesus macaques. In addition, this approach offers a safe alternative to live attenuated vaccines and DNA vaccines that are capable of integration.

Original languageEnglish (US)
Pages (from-to)343-351
Number of pages9
JournalViral Immunology
Volume13
Issue number3
StatePublished - 2000

Fingerprint

Simian Immunodeficiency Virus
DNA Vaccines
Acquired Immunodeficiency Syndrome
Vaccines
Defective Viruses
DNA
Genome
Macaca mulatta
Virion
Plasmids
pol Genes
Viral Envelope Proteins
vpr Genes
gag Gene Products
Integrases
Attenuated Vaccines
Gene Fusion
Humoral Immunity
Cytomegalovirus
Cellular Immunity

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Preparation and induction of immune responses by a DNA AIDS vaccine. / Smith, J. M.; Leung, N. J.; Torres, Jose V.

In: Viral Immunology, Vol. 13, No. 3, 2000, p. 343-351.

Research output: Contribution to journalArticle

Smith, J. M. ; Leung, N. J. ; Torres, Jose V. / Preparation and induction of immune responses by a DNA AIDS vaccine. In: Viral Immunology. 2000 ; Vol. 13, No. 3. pp. 343-351.
@article{9f43034c5687471a9fdc3b8616a046af,
title = "Preparation and induction of immune responses by a DNA AIDS vaccine",
abstract = "In an effort to evaluate the feasibility of developing a safe DNA vaccine for acquired immunodeficiency syndrome (AIDS), we have prepared a plasmid-based immunogen modeled after a naturally occurring noninfectious mutant of the simian immunodeficiency virus (SIV). The mutant SIV genome produces defective virus particles that are noninfectious in vitro and nonpathogenic in vivo in rhesus macaques. Analysis of the mutant genome revealed a 1.6 kb deletion that is in frame and spans integrase, vif, vpx, and most of vpr and results in a pol/vpr gene fusion. This deletion was introduced into the parental pathogenic molecular clone and the U3 region of the 5' LTR was replaced with a cytomegalovirus promoter to produce a candidate DNA vaccine, pIV. After transfection with this plasmid, SIV gag and envelope proteins are expressed and properly processed in vitro. When injected into rabbits, pIV elicited an antibody response to SIV gp130 envelope glycoprotein with titers reaching 1:2048, and a strong lymphoproliferative response to SIV gp130 and whole SIV. The potential to produce defective virus particles in vivo without integrating into the host genome should result in both a strong humoral and cellular immune response in rhesus macaques. In addition, this approach offers a safe alternative to live attenuated vaccines and DNA vaccines that are capable of integration.",
author = "Smith, {J. M.} and Leung, {N. J.} and Torres, {Jose V}",
year = "2000",
language = "English (US)",
volume = "13",
pages = "343--351",
journal = "Viral Immunology",
issn = "0882-8245",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Preparation and induction of immune responses by a DNA AIDS vaccine

AU - Smith, J. M.

AU - Leung, N. J.

AU - Torres, Jose V

PY - 2000

Y1 - 2000

N2 - In an effort to evaluate the feasibility of developing a safe DNA vaccine for acquired immunodeficiency syndrome (AIDS), we have prepared a plasmid-based immunogen modeled after a naturally occurring noninfectious mutant of the simian immunodeficiency virus (SIV). The mutant SIV genome produces defective virus particles that are noninfectious in vitro and nonpathogenic in vivo in rhesus macaques. Analysis of the mutant genome revealed a 1.6 kb deletion that is in frame and spans integrase, vif, vpx, and most of vpr and results in a pol/vpr gene fusion. This deletion was introduced into the parental pathogenic molecular clone and the U3 region of the 5' LTR was replaced with a cytomegalovirus promoter to produce a candidate DNA vaccine, pIV. After transfection with this plasmid, SIV gag and envelope proteins are expressed and properly processed in vitro. When injected into rabbits, pIV elicited an antibody response to SIV gp130 envelope glycoprotein with titers reaching 1:2048, and a strong lymphoproliferative response to SIV gp130 and whole SIV. The potential to produce defective virus particles in vivo without integrating into the host genome should result in both a strong humoral and cellular immune response in rhesus macaques. In addition, this approach offers a safe alternative to live attenuated vaccines and DNA vaccines that are capable of integration.

AB - In an effort to evaluate the feasibility of developing a safe DNA vaccine for acquired immunodeficiency syndrome (AIDS), we have prepared a plasmid-based immunogen modeled after a naturally occurring noninfectious mutant of the simian immunodeficiency virus (SIV). The mutant SIV genome produces defective virus particles that are noninfectious in vitro and nonpathogenic in vivo in rhesus macaques. Analysis of the mutant genome revealed a 1.6 kb deletion that is in frame and spans integrase, vif, vpx, and most of vpr and results in a pol/vpr gene fusion. This deletion was introduced into the parental pathogenic molecular clone and the U3 region of the 5' LTR was replaced with a cytomegalovirus promoter to produce a candidate DNA vaccine, pIV. After transfection with this plasmid, SIV gag and envelope proteins are expressed and properly processed in vitro. When injected into rabbits, pIV elicited an antibody response to SIV gp130 envelope glycoprotein with titers reaching 1:2048, and a strong lymphoproliferative response to SIV gp130 and whole SIV. The potential to produce defective virus particles in vivo without integrating into the host genome should result in both a strong humoral and cellular immune response in rhesus macaques. In addition, this approach offers a safe alternative to live attenuated vaccines and DNA vaccines that are capable of integration.

UR - http://www.scopus.com/inward/record.url?scp=0033808053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033808053&partnerID=8YFLogxK

M3 - Article

C2 - 11016598

AN - SCOPUS:0033808053

VL - 13

SP - 343

EP - 351

JO - Viral Immunology

JF - Viral Immunology

SN - 0882-8245

IS - 3

ER -